



EGYPT

Number of new cases

150 578

Number of deaths


95 275

Number of prevalent cases (5-year)

366 823


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	53 629 377	52 527 315	106 156 692
Incidence*			
Number of new cancer cases	73 611	76 967	150 578
Age-standardized incidence rate	175.1	161.1	166.1
Risk of developing cancer before the age of 75 years (cum. risk %)	18.3	16.1	17.1
Top 3 leading cancers (ranked by cases)**	Liver Bladder Lung	Breast Liver NHL	Liver Breast Bladder
Mortality*			
Number of cancer deaths	51 692	43 583	95 275
Age-standardized mortality rate	127.4	92.2	107.7
Risk of dying from cancer before the age of 75 years (cum. risk %)	12.9	9.5	11.2
Top 3 leading cancers (ranked by deaths)**	Liver Bladder Lung	Liver Breast NHL	Liver Breast Bladder
Prevalence*			
5-year prevalent cases	164 427	202 396	366 823



Top 5 most frequent cancers**


Males



Rank	Cancer site	Number of cases	Percent
1st	Liver	17 759	24.1%
2nd	Bladder	10 416	14.2%
3rd	Lung	5 599	7.6%
4th	Prostate	5 181	7.0%
5th	NHL	4 699	6.4%
-	Others	29 957	40.7%

Number of new cases in 2022, males, all ages


Females



Rank	Cancer site	Number of cases	Percent
1st	Breast	26 845	34.9%
2nd	Liver	10 187	13.2%
3rd	NHL	4 162	5.4%
4th	Ovary	3 070	4.0%
5th	Colorectum	3 001	3.9%
-	Others	29 702	38.6%

Number of new cases in 2022, females, all ages

Both sexes



Rank	Cancer site	Number of cases	Percent
1st	Liver	27 946	18.6%
2nd	Breast	26 845	17.8%
3rd	Bladder	13 097	8.7%
4th	NHL	8 861	5.9%
5th	Lung	7 643	5.1%
-	Others	66 186	44.0%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Liver	27 946	1	18.6	3.7	26 971	1	28.3	3.6	39 028	36.8
Breast	26 845	2	17.8	5.7	9 596	2	10.1	2.1	81 661	155.5
Bladder	13 097	3	8.7	1.9	7 481	3	7.9	0.90	38 603	36.4
NHL	8 861	4	5.9	1.0	4 593	5	4.8	0.55	27 409	25.8
Lung	7 643	5	5.1	1.1	6 805	4	7.1	0.94	10 559	10.0
Leukaemia	6 194	6	4.1	0.61	4 371	6	4.6	0.50	18 537	17.5
Colorectum	5 940	7	3.9	0.70	3 096	9	3.3	0.34	16 596	15.6
Prostate	5 181	8	3.4	1.6	2 102	11	2.2	0.24	11 541	21.5
Brain CNS	4 452	9	3.0	0.44	3 611	7	3.8	0.39	15 700	14.8
Pancreas	3 349	10	2.2	0.46	3 186	8	3.3	0.44	3 949	3.7
Stomach	3 285	11	2.2	0.42	2 469	10	2.6	0.31	5 516	5.2
Ovary	3 070	12	2.0	0.69	1 944	12	2.0	0.48	8 683	16.5
Thyroid	2 612	13	1.7	0.29	483	20	0.51	0.04	7 878	7.4
Kidney	2 259	14	1.5	0.26	990	15	1.0	0.10	6 665	6.3
Corpus uteri	2 048	15	1.4	0.54	425	21	0.45	0.10	6 736	12.8
Larynx	1 814	16	1.2	0.26	1 283	14	1.3	0.16	5 339	5.0
Hodgkin lymphoma	1 684	17	1.1	0.13	419	22	0.44	0.03	5 972	5.6
Lip, oral cavity	1 578	18	1.0	0.20	659	18	0.69	0.08	4 461	4.2
Oesophagus	1 543	19	1.0	0.21	1 510	13	1.6	0.21	2 340	2.2
Cervix uteri	1 302	20	0.87	0.31	820	16	0.86	0.21	3 536	6.7
Multiple myeloma	904	21	0.60	0.12	771	17	0.81	0.11	2 590	2.4
Gallbladder	787	22	0.52	0.10	578	19	0.61	0.08	1 216	1.2
Salivary glands	452	23	0.30	0.05	191	24	0.20	0.02	1 293	1.2
Mesothelioma	375	24	0.25	0.05	335	23	0.35	0.04	513	0.48
Nasopharynx	308	25	0.21	0.03	159	26	0.17	0.01	912	0.86
Testis	304	26	0.20	0.05	55	30	0.06	0.01	1 041	1.9
Hypopharynx	264	27	0.18	0.03	167	25	0.18	0.02	480	0.45
Vulva	253	28	0.17	0.06	137	27	0.14	0.03	648	1.2
Melanoma	222	29	0.15	0.03	81	28	0.09	0.01	704	0.66
Oropharynx	182	30	0.12	0.02	67	29	0.07	0.01	556	0.52
Vagina	95	31	0.06	0.03	39	31	0.04	0.01	245	0.47
Kaposi sarcoma	84	32	0.06	0.01	27	32	0.03	0.01	136	0.13
All cancers	150 578	-	-	17.1	95 275	-	-	11.2	366 823	-
All cancers excl. NMSC	148 639	-	-	16.9	94 069	-	-	11.0	360 720	-

Data source and methods

Incidence



Country-specific data source: Gharbiah cancer registry
Method: Most recent rates from a single registry applied to 2022 population

Mortality

Country-specific data source: No data
Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

